Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) vs Newer (Nonergot) Dopamine Agonists
Open Access
- 1 January 2004
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 61 (1), 97-102
- https://doi.org/10.1001/archneur.61.1.97
Abstract
The newer nonergot dopamine agonists pramipexole dihydrochloride and ropinirole hydrochloride are efficacious in early Parkinson disease (PD) and may be associated with fewer motor fluctuations and dyskinesias than levodopa.1,2 Both are effective adjuncts to levodopa therapy in advanced PD, and their exhibited levodopa-sparing effect may offer a neuroprotective potential in reducing dopamine oxidation metabolism.3Keywords
This publication has 15 references indexed in Scilit:
- Schwab and England Activities of Daily Living ScalePublished by Elsevier BV ,2010
- Daytime sleepiness and other sleep disorders in Parkinson’s diseaseNeurology, 2002
- Sleep Attacks and Antiparkinsonian Drugs: A Pilot Prospective Pharmacoepidemiologic StudyClinical Neuropharmacology, 2001
- Non‐Ergot Dopamine Agonist‐Induced Sleep AttacksPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- Sleep attacks (sleep episodes) with pergolideThe Lancet, 2000
- Ropinirole and pramipexole, the new agonists.Canadian Journal of Neurological Sciences, 1999
- Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropiniroleNeurology, 1999
- Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in ratsEuropean Neuropsychopharmacology, 1998
- Subjective and Objective Sleepiness in the Active IndividualInternational Journal of Neuroscience, 1990
- ParkinsonismNeurology, 1967